A Randomised, Observer-Blind Trial to Evaluate the Immunogenicity, Safety, and Reactogenicity of a Group B Streptococcus Vaccine (GBS-NN/NN-2) when 1 Dose is Administered Concomitantly with the TDaP Vaccine in Healthy Non-pregnant Women 18 to 49 years of age Compared to when Each Vaccine is Administered Alone
Not yet recruitingCTIS2023-508563-73-00
Minervax ApSPrevention of Group B streptococcus infection
Target: 564Updated: 2024-10-31